InfiCure Bio offer advanced drug validation services for pharmaceutical companies developing drugs against fibrosis – or scar tissue formation in organs. The shortage of existing model systems that reflect human fibrotic disease conditions, make this a very attractive CRO-service for pharmaceutical developers.
Lipum develops a biological pharmaceutical for a novel mechanism of action in the treatment of chronic inflammations. The lead candidate drug (SOL-116) is a monoclonal antibody directed towards the protein bile salt-stimulated lipase, BSSL. One indication is as an orphan drug for the more severe forms of Juvenile Idiopathic Arthritis (JIA), providing patients with an effective treatment alternative having less adverse effects than the drugs used today.
By combining two different methods, Medsens AB is aiming at offering a whole new tool for realtime microdiagnostics during prostate cancer surgery. The company’s instrument is far more accurate that the methods used by clinicians today – which could make surginal procedures much more efficient. The project is based on the work of Olof Lindahl och Kerstin Ramser.
We are developing safe and resistance-breaking molecules that target an enzyme essential for nerve signaling in mosquitoes via a new mode of action. In contrast to current insecticides, we have designed our molecules to specifically target mosquitoes, without affecting other organisms.
Brain stimulation offer digital evidence-based virtual reality rehabilitation for improved quality of life for stroke patients. We offer an accessible treatment strategy for patients suffering from neglect with shorter stay at hospital and eventually less need of support in their daily life.
Acne vulgaris affects more than 80 percent of people at some point in their life and frequently continues into adulthood. Recent data suggest that there are about 680 million people living with acne around the world. This case focuses on a novel approach to decrease the risk of acne by promoting healthy skin without the hazards of antibiotic resistance development.
MetaCurUm Biotech is developing a novel antibody treatment for metastatic cancers. The company´s drug development program is focused on transforming growth factor-beta (TGFβ) driven cancers, with the aim to optimize the treatment paradigms in aggressive forms of cancer with high unmet medical need such as prostate, lung, kidney, and endometrial cancer.
Shades of Green, led by Daniel Pacurar of Boreal Orchards, is developing innovative approaches for sustainable and adaptive greening solutions both for urban environments and for restoring disturbed ecosystems. The aim is to create moss-coated solutions for outdoor and indoor spaces that are both functional and aesthetic.
Cyanobacteria have significant potential as industrial biotechnology platforms to produce a wide variety of bio-products, such as polymers, sugars and powerful antioxidants such as C-phycocyanin. Our team have created a set of genetic tools that give significant advantages in the microalgae industry for save, efficient and specific bioproduction.
Recurrent aphthous ulcers (RAS) are mouth ulcers that can last for more than a week at each occasion and during that period patients often suffer and need sick leave. About 80% of all patient’s state that the pain from RAS is the main symptom. The innovative oral patch (MO45A) shields the ulcer giving instant pain relief and improves healing primarily through it´s extensive hygroscopic effect.
Delayed or inappropriate treatment of anaerobic infections may result in severe disease or death. With knowledge levels dropping at many clinical laboratories, the need for anaerobic proficiency increases. Dianox is developing educational solutions to halt this trend in health care.
We are developing a targeted mass-spectrometry biomarker tool for differentiating subgroups of patients with Parkinsonian disorders exhibiting similar clinical symptoms but having distinct molecular etiologies of neurological disease.
Current drugs against mycoses are toxic. We aim to develop a new class of antifungal agents that disarm the invasive forms of fungal cells instead of merely eradicating them. This has two advantages: The new compounds are less aggressive for the host and resistance development is reduced.
Prostate cancer (PC) is a common and multifocal disease, with symptoms ranging from harmless to lethal. In Sweden, about 10000 new cases are diagnosed every year.
QureTech Bio develops new first-in-class antibacterial agents to combat infectious diseases and the occurrence of antibiotic resistance. This is done either by a direct antimicrobial effect or by potentiating existing antibiotics and making them more effective without causing resistance.
Pro Test Diagnostics has developed a routine test to monitor and detect illegal use of one’s own stored blood to enhance performance in elite athletes. The ABT™-test can expose athletes who have used blood doping and the result is not affected by the athlete’s training intensity, the use of high-altitude training or the use of low oxygen tents.
A natural compound-approach for neutralizing exotoxins from various gram-negative pathogens. Gobroxia AB has developed a novel method to treat pathogens causing diseases such as diarrhea, sepsis, tooth loss and whooping cough in humans, as well as bovine respiratory disease in cattle and pneumonia in pigs.
